Adjunctive efficacy of systemic metronidazole in the surgical treatment of periodontitis: a randomized placebo-controlled clinical trial

Pontificia Universidad Católica Madre y Maestra0 个研究点目标入组 40 人开始时间: 2020年12月4日最近更新: 2022年10月10日

适应症

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35122549/ (added 14/03/2022)

•1. Severe generalized chronic periodontitis (Armitage, 1999), corresponding to generalized stage III-IV periodontitis, with grades B-C (Caton et al., 2018; Papapanou et al., 2018; Tonetti, Greenwell, & Kornman, 2018)
•2. A least 10 teeth in function, excluding third molars
•3. Sites with PD> 5 mm, in =2 teeth in =1 quadrant
•4. Radiographic evidence of bone loss =30% in, at least, 30% of the dentition
•5. Older than 18 years

•1. Pregnant or breastfeeding women
•2. Systemic diseases and/or chronic medications that may affect the periodontal status and /or requiring antibiotic prophylaxis
•3. Having received systemic antimicrobial treatment in the previous 3 months
•4. Have received periodontal treatment in the 6 months prior to the start of the study
•5. Allergic to metronidazole, or to any of the components of their commercial formulations (Metrex 500 mg®, Laboratorio Union SRL, Santo Domingo, República Dominicana)
•6. Refuse to sign the informed consent
•7. Smokers =10 cigarettes/day

发起方

Pontificia Universidad Católica Madre y Maestra